Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down – Should You Sell?

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) gapped down before the market opened on Wednesday . The stock had previously closed at $18.49, but opened at $16.50. Ono Pharmaceutical shares last traded at $16.50, with a volume of 400 shares traded.

Ono Pharmaceutical Stock Down 10.8%

The firm has a 50-day simple moving average of $14.34 and a 200 day simple moving average of $12.61. The stock has a market capitalization of $7.75 billion, a P/E ratio of 18.54 and a beta of 0.25. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.02 and a quick ratio of 2.56.

Ono Pharmaceutical (OTCMKTS:OPHLF) last released its quarterly earnings results on Monday, February 2nd. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.11. Ono Pharmaceutical had a return on equity of 7.76% and a net margin of 12.29%.The company had revenue of $892.70 million for the quarter, compared to analysts’ expectations of $727.58 million.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.